A multicultural group practicing yoga together in a bright studio

Embody vs Trimi: GLP-1 Comparison 2026

Embody vs Trimi: pricing, medication type, clinical support, and which budget-conscious GLP-1 patient each program fits. Both programs’ prices verified August 2026 or later; each price carries its own date in the table below.

By RangeYourselfUpdated August 21, 20264 min read

Quick answer

Trimi typically wins on sticker price for compounded GLP-1. Both prescribe compounded medication, so compare them on the specific product, plan term, and terms you'd actually be buying rather than on program positioning.

Side-by-side comparison

Feature	Embody	Trimi
Best for	Personalized compounded blends and hands-on support	Lowest-cost compounded GLP-1 on an annual plan with a plain 503A disclosure
Medication type	Compounded GLP-1 with personalization	Compounded semaglutide and compounded tirzepatide, once-weekly at-home injection
Pricing model	Monthly subscription, formulation-tiered	Flat-membership subscription billed yearly (annual commitment tier); one price covers medication, clinician visits, check-ins, shipping; no separate membership fee; no insurance
Semaglutide price	Compounded, $69/mo (limited-time promo, was $299), verified 2026-08-21; confirm current price at checkout. Standard/recurring price not publicly listed. (Same offer showed $99/mo and $149/mo promos on 2026-07-14, see price history.)	Compounded, $99/mo on the annual plan, BILLED YEARLY ($1,188/yr up front). Verified 2026-08-21 (unchanged since 2026-07-14).
Tirzepatide price	Compounded tirzepatide / GLP-1+GIP, $119/mo (flat pricing shown on the verified offer page), verified 2026-08-21; no 'was' comparison price shown for tirzepatide specifically, confirm at signup.	Compounded, $125/mo on the annual plan (billed yearly). Verified 2026-08-21 (unchanged since 2026-07-14).
Key watchout	Embody's published price is a live time-limited promo with no confirmed standing rate: it changed intra-day on 2026-07-14 ($99/mo AM, '$200 OFF, was $299', to $149/mo PM, '$150 OFF, was $299'), and by 2026-08-21 the same offer URL had dropped further to a new low. We rank it at its current verified purchasable price ($69/mo semaglutide) and label it a promo, confirm the exact cost at checkout. Custom blends also warrant scrutiny on ingredient transparency.	The $99/mo semaglutide and $125/mo tirzepatide rates are the ANNUAL plan, BILLED YEARLY (semaglutide = $1,188 charged up front). A month-to-month rate is not published, confirm billing terms before enrolling.
Price checked	Checked by a person August 21, 2026 · an automated check re-read it September 3, 2026	Checked by a person August 21, 2026 · an automated check re-read it September 3, 2026

When to choose Embody

You want a compounded program that personalizes the formulation
You're comfortable evaluating ingredient lists and provider transparency
You'd value bundled adjuncts (anti-nausea, B12, etc.) when offered
You're escalating dose and want a provider that adjusts with you

Check current Embody pricing →

When to choose Trimi

You want the lowest-cost compounded semaglutide ($99/mo) or tirzepatide ($125/mo) with everything bundled
You’re comfortable with an annual plan billed yearly ($1,188 up front for semaglutide)
You value an upfront '503A compounding pharmacy' and 'not FDA-approved' disclosure
You want care via a 50-state clinical network (Arora Health) with free shipping

Check current Trimi pricing →

Full reviews

Frequently asked questions

Is Embody cheaper than Trimi?

Embody starts lower on semaglutide (Compounded, $69/mo (limited-time promo, was $299), verified 2026-08-21; confirm current price at checkout. Standard/recurring price not publicly listed. (Same offer showed $99/mo and $149/mo promos on 2026-07-14, see price history.)). Embody starts lower on tirzepatide (Compounded tirzepatide / GLP-1+GIP, $119/mo (flat pricing shown on the verified offer page), verified 2026-08-21; no 'was' comparison price shown for tirzepatide specifically, confirm at signup.). Higher doses can shift the picture, so confirm pricing at the dose you're likely to use long-term.

Which is better for semaglutide or tirzepatide, Embody or Trimi?

Embody starts lower on both semaglutide and tirzepatide based on listed entry pricing. That said, the right pick is the program whose support model and formulation match what you actually need.

Are Embody and Trimi compounded or brand-name?

Embody offers compounded glp-1 with personalization. Trimi offers compounded semaglutide and compounded tirzepatide, once-weekly at-home injection. If you specifically want brand-name Wegovy or Zepbound, lean toward whichever explicitly supports brand access; if compounded is fine, both can typically meet that need.

Can I switch from Embody to Trimi?

Yes, switching between Embody and Trimi is straightforward in most states. You typically finish your current month, complete a new intake with the other provider, and they handle the prescription. Watch for overlap on auto-renewal billing and confirm any dose-tier or formulation differences with the new clinician before your next shipment.

Compare Embody and Trimi to other programs

Alert me when this gets cheaper

These prices move. Get one email when we publish a verified price drop, the programs on this list included. No spam. Unsubscribe any time.

Related guides

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Pricing reflects publicly listed entry tiers, verified on the dates shown in the table above, and may change. Numbers like Compounded, $69/mo (limited-time promo, was $299), verified 2026-08-21; confirm current price at checkout. Standard/recurring price not publicly listed. (Same offer showed $99/mo and $149/mo promos on 2026-07-14, see price history.) and Compounded, $99/mo on the annual plan, BILLED YEARLY ($1,188/yr up front). Verified 2026-08-21 (unchanged since 2026-07-14). are starting tiers, not your guaranteed long-term cost.